Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial

被引：0
|
作者：
Bagel, J. [1 ]
Nia, J. [2 ]
Hashim, P. [2 ]
Patekar, M. [3 ]
de Vera, A. [3 ]
Hugot, S. [3 ]
Sheng, K. [4 ]
Xia, S. [5 ]
Gilloteau, I. [3 ]
Blauvelt, A. [6 ]
Lebwohl, M. [2 ]
Bian, M. [7 ]
机构：
[1] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Oregon Med Res Ctr, Portland, OR USA
[7] Novartis Pharmaceut Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
    Van Voorhees, Abby S.
    Gold, Linda Stein
    Lebwohl, Mark
    Strober, Bruce
    Lynde, Charles
    Tyring, Stephen
    Cauthen, Ashley
    Sofen, Howard
    Zhang, Zuoshun
    Paris, Maria
    Wang, Yao
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 96 - 103
  • [32] Apremilast in patients with moderate to severe psoriasis: Results of a phase 3, randomized, controlled trial (ESTEEM 2)
    Mrowietz, U.
    Paul, C.
    Gooderham, M.
    Cather, J.
    Poulin, Y.
    Girolomoni, G.
    Ferrandiz, C.
    Gottlieb, A.
    Hu, C. C.
    Day, R.
    Crowley, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 93 - 94
  • [33] Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial
    Landells, Ian
    Marano, Collen
    Hsu, Ming-Chun
    Li, Shu
    Eichenfield, Lawrence
    Hoeger, Peter
    Menter, Alan
    Paller, Amy
    Taieb, Alain
    Randazzo, Bruce
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB202 - AB202
  • [34] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis
    Ryan, C.
    Menter, A.
    Guenther, L.
    Blauvelt, A.
    Bissonnette, R.
    Yang, F. E.
    Bleakman, A. Potts
    Burkhardt, N.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 42 - 42
  • [35] EFFICACY AND SAFETY OF IXEKIZUMAB IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3B CLINICAL TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS
    Ryan, C.
    Menter, A.
    Guenther, L.
    Blauvelt, A.
    Bissonnette, R.
    Yang, F. E.
    Bleakman, Potts A.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (02): : S6 - S7
  • [36] Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis
    Ryan, Caitriona
    Menter, Alan
    Guenther, Lyn
    Blauvelt, Andrew
    Bissonnette, Robert
    Yang, Fan Emily
    Bleakman, Alison Potts
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 13 - 14
  • [37] Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn's Disease: Results From the Phase 3B SEQUENCE Trial
    Peyrin-Biroulet, Laurent
    Chapman, Casey
    Colombel, Jean-Frederic
    Caprioli, Flavio
    D'Haens, Geert
    Ferrante, Marc
    Schreiber, Stefan
    Atreya, Raja
    Danese, Silvio
    Lindsay, James O.
    Bossuyt, Peter
    Siegmund, Britta
    Irving, Peter
    Panaccione, Remo
    Neimark, Ezequiel
    Wallace, Kori
    Anschutz, Toni
    Kligys, Kristina
    Duan, W. Rachel
    Pivorunas, Valerie
    Huang, Xiu
    Berg, Sofie
    Shu, Lei
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S1 - S1
  • [38] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
    Blauvelt, Andrew
    Wu, Jashin J.
    Reich, Kristian
    Gooderham, Melinda
    Lebwohl, Mark
    White, Katy
    Cross, Nancy
    Cioffi, Christopher
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
  • [39] A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
    Gelfand, Joel M.
    Shin, Daniel B.
    Duffin, Kristina Callis
    Armstrong, April W.
    Blauvelt, Andrew
    Tyring, Stephen K.
    Menter, Alan
    Gottlieb, Scott
    Lockshin, Benjamin N.
    Simpson, Eric L.
    Kianifard, Farid
    Sarkar, Rajendra Prasad
    Muscianisi, Elisa
    Steadman, Jennifer
    Ahlman, Mark A.
    Playford, Martin P.
    Joshi, Aditya A.
    Dey, Amit K.
    Werner, Thomas J.
    Alavi, Abass
    Mehta, Nehal N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (09) : 1784 - +
  • [40] IXEKIZUMAB PROVIDES GREATER CUMULATIVE BENEFITS VERSUS USTEKINUMAB OVER 24 WEEKS FOR PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN A RANDOMIZED, DOUBLE-BLIND PHASE 3B CLINICAL TRIAL
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Henneges, Carsten
    Shen, Wei
    Shrom, David
    Dossenbach, Martin
    Pinter, Andreas
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 55 - 56
12345